Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-592-6 | CAS number: 143-22-6
Endpoint summary
Administrative data
Description of key information
Study |
Result |
Comment |
TEGBE |
||
21 day dermal repeat dose study in rabbits |
[NOAEL (local irritation): <1000mg/kgbw/day] NOAEL (all other effects): >1000mg/kgbw/day - no adverse effects at maximum tested dose |
|
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 500 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Predictions are based on a weighted average consideration of the results for this substance and other substances within the category. Results corrected for molecular weight differences. There is no data on the repeat dose toxicity of this substance from studies to modern guidelines. A sub-chronic bridging study is being carried out on this substance followig a compliance check decision.
Justification for classification or non-classification
Repeat toxicity studies are available for source substances within the category by both the dermal and oral routes. (Inhalation is not considered relevant due to the very low vapour pressure of TEBE). For the oral route, classification is only required if significant toxic effects are seen at a dose of 100mg/kg or lower and 200mg/kg for the dermal route. From the available data it can be concluded with some confidence that TEGBE is not likely to meet these criteria and therefore classification is not required.
The necessity to apply EUH066 for the skin effects seen in the sub-acute dermal repeat dose studies should be considered. However, since the effects produced by the source substances are not considered sufficient to warrant applying this phrase, it is not considered appropriate to apply it to TEGBE.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
